ChiCTR2400085464 版本V1.0 版本创建时间2024/06/07 15:06:24 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400085464 

最近更新日期:

Date of Last Refreshed on:

2024-06-07 15:06:14 

注册时间:

Date of Registration:

2024-06-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于多模态预测模型的社交工具开发及其对女性膝关节骨关节炎预防效果的随机对照试验研究

Public title:

A randomized controlled trial study on the development of a social tool based on a multimodal predictive model and its preventive effect on female knee osteoarthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于多模态预测模型的社交工具开发及其对女性膝关节骨关节炎预防效果的随机对照试验研究

Scientific title:

A randomized controlled trial study on the development of a social tool based on a multimodal predictive model and its preventive effect on female knee osteoarthritis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王德利 

研究负责人:

王德利 

Applicant:

Deli Wang 

Study leader:

Deli Wang 

申请注册联系人电话:

Applicant telephone:

+86 188 2346 3328

研究负责人电话:

Study leader's telephone:

+86 188 2346 3328

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangdelinavy@163.com

研究负责人电子邮件:

Study leader's E-mail:

wangdelinavy@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市福田区莲花路1120号

研究负责人通讯地址:

广东省深圳市福田区莲花路1120号

Applicant address:

1120 Lianhua Road, Futian District, Shenzhen City, Guangdong Province

Study leader's address:

1120 Lianhua Road, Futian District, Shenzhen City, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学深圳医院

Applicant's institution:

Peking University Shenzhen Hospital

研究负责人所在单位:

北京大学深圳医院

Affiliation of the Leader:

Peking University Shenzhen Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

北大深医伦审(研)[2022]第(132)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京大学深圳医院科研伦理委员会

Name of the ethic committee:

Research Ethics Committee of Peking University Shenzhen Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-10-08 00:00:00

伦理委员会联系人:

陈嘉怡

Contact Name of the ethic committee:

Jiayi Chen

伦理委员会联系地址:

广东省深圳市福田区莲花路1120号北京大学深圳医院

Contact Address of the ethic committee:

Peking University Shenzhen Hospital, 1120 Lianhua Road, Futian District, Shenzhen City, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 83923333

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学深圳医院

Primary sponsor:

Peking University Shenzhen Hospital

研究实施负责(组长)单位地址:

广东省深圳市福田区莲花路1120号

Primary sponsor's address:

1120 Lianhua Road, Futian District, Shenzhen City, Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

深圳市

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

北京大学深圳医院

具体地址:

广东省深圳市福田区莲花路1120号

Institution
hospital:

Peking University Shenzhen Hospital

Address:

1120 Lianhua Road, Futian District, Shenzhen City, Guangdong Province

经费或物资来源:

北京大学深圳医院院内课题项目

Source(s) of funding:

Research Foundation of Peking University Shenzhen Hospital

Target disease:

Knee Osteoarthritis in women

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

运用血清蛋白组和代谢组的多组学整合分析,明确女性绝经后发生膝关节骨关节炎的特征性生物标志物;通过多模态数据,完成女性绝经后膝关节骨关节炎发生风险多模态预测模型的构建和验证;基于女性绝经后膝关节骨关节炎发生风险多模态预测模型,建立具有风险提醒、健康生活指导等功能的手机 APP,评价其对女性绝经后骨关节炎发病风险人群一级预防的效果。  

Objectives of Study:

The characteristic biomarkers of knee osteoarthritis in postmenopausal women were identified by multi-omics integration analysis of serum proteome and metabolome. Through the multi-modal data, the multi-modal prediction model of the risk of female postmenopausal knee osteoarthritis was constructed and verified. Based on the multi-modal prediction model of the occurrence risk of female postmenopausal knee osteoarthritis, a mobile phone APP with functions such as risk reminder and healthy life guidance was established to evaluate its effect on the primary prevention of female postmenopausal osteoarthritis risk groups.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.北京大学深圳医院骨关节科门诊就诊女性患者; 2.年龄在 45-55 岁之间; 3.体重指数在20-35 kg/m2之间; 4.膝关节 K-L 分级小于2级; 5.WOMAC评分小于10分; 6.膝关节静息或者运动VAS评分小于等于3分,且疼痛为偶发; 7.经过女性绝经后膝关节骨关节炎发生风险多模态预测模型预测为高风险患者; 8.签署知情同意书。

Inclusion criteria

1. Female patients in the outpatient Department of Osteoarthrosis, Peking University Shenzhen Hospital. 2. Between 45 and 55 years old. 3. Body mass index between 20-35 kg/m2. 4. K-L grade of knee joint is less than grade 2. 5. WOMAC score is less than 10 points. 6. The knee resting or exercise VAS score was less than or equal to 3 points, and the pain was sporadic. 7. Multimodal prediction models predict the risk of knee osteoarthritis in postmenopausal women as high-risk patients. 8. Sign the informed consent form.

排除标准:

1.膝关节手术病史、感染病史、创伤史的女性; 2.膝关节僵直、强直的女性; 3.3级肌力及以下患者; 4.长期避孕药运用病史女性; 5.患有妇科肿瘤女性; 6.伴有糖尿病等慢性代谢性疾病的女性; 7.语言障碍、智力障碍不能完成项目所需量表检测及检查的女性; 8.中枢或者外周神经病变影响患者正常行走及功能锻炼等女性; 9.既往存在消化道溃疡的女性; 10.因各种原因不能配合完成试验的女性。

Exclusion criteria:

1. Women with history of knee surgery, history of knee infection, history of knee trauma. 2. Women with knee joint stiffness and ankylosis. 3. Patients with muscle strength grade 3 and below. 4. Women with a long history of contraceptive use. 5. Women with gynecological tumors. 6. Women with chronic metabolic diseases such as diabetes. 7. Women with language and intellectual disabilities who cannot complete the scale detection and examination required by the project. 8. Women with central or peripheral neuropathy affecting normal walking and functional exercise. 9. Women with previous digestive tract ulcers. 10. Women who, for various reasons, were unable to complete the study.

研究实施时间:

Study execute time:

From 2024-06-01 00:00:00 To 2031-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-06-15 00:00:00 To 2031-06-15 00:00:00  

干预措施:

Interventions:

组别:

队列研究组

样本量:

720

Group:

Cohort study group

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

组别:

常规干预组

样本量:

133

Group:

Routine intervention group

Sample size:

干预措施:

常规口头及文字指导

干预措施代码:

Intervention:

Regular verbal and written guidance

Intervention code:

组别:

APP干预组

样本量:

133

Group:

APP intervention group

Sample size:

干预措施:

使用APP进行干预指导

干预措施代码:

Intervention:

Using an APP for intervention guidance

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

深圳市 

Country:

China 

Province:

Guangdong 

City:

Shenzhen 

单位(医院):

北京大学深圳医院 

单位级别:

三级甲等 

Institution
hospital:

Peking University Shenzhen Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

膝关节骨关节炎发病率

指标类型:

主要指标

Outcome:

Incidence rate of knee osteoarthritis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膝关节正位 X 光 K-L 分级 2 级及以上

指标类型:

主要指标

Outcome:

Knee joint ortho X-ray K-L grade 2 or above

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膝关节正位 X 光上,膝关节内侧或者外侧间室关节间隙较基线的变化

指标类型:

次要指标

Outcome:

Changes in the joint space between the medial or lateral compartments of the knee joint from baseline on X-rays of the knee joint in an upright position

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

静息和运动情况下 VAS 评分

指标类型:

次要指标

Outcome:

VAS score under resting and exercise conditions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膝关节功能 WOMAC 评分

指标类型:

次要指标

Outcome:

WOMAC score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

股四头肌肌力测量

指标类型:

次要指标

Outcome:

Measurement of quadriceps muscle strength

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SF-36 评分

指标类型:

次要指标

Outcome:

SF-36 score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清生物标志物

指标类型:

次要指标

Outcome:

Serum biomarkers

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血清

组织:

Sample Name:

Serum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 45 years
最大 Max age 55 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

由科研秘书运用 SPSS 软件生成的随机数字表产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomized grouping by the research secretary using a random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

单盲(对受试者隐藏分组)

Blinding:

Single-blinded (hidden grouping of subjects)

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

日期:本项目结束后一个月(2031年8月1日) 方式:ResMan ( http://www.medresman.org.cn/ )

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Date: one month after project completion (August 1, 2031) Method: ResMan ( http://www.medresman.org.cn/ )

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例报告表和电子数据采集(ResMan)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and electronic data capture (ResMan)

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-06-07 15:06:14